[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573474":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":43,"responsibleParty":93,"collaborators":95,"id":99,"slug":100,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":101,"sex":107,"minAge":108,"maxAge":25,"enrollmentInfo":109,"targetDuration":25,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":122,"whyStopped":25,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"Wake Forest University Health Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Angiotensin II","EXPERIMENTAL","Continuous infusion of Angiotensin II for up to 48 hours",[13],"Drug: Angiotensin II",{"label":15,"type":16,"description":17,"interventionNames":18},"Norepinephrine","ACTIVE_COMPARATOR","Continuous infusion of Norepinephrine for up to 48 hours",[19],"Drug: Norepinephrine",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","randomized to receive Angiotensin II continuous infusion for up to 48 hours",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"randomized to receive Norepinephrine continuous infusion for up to 48 hours",[15],[30],{"name":31,"affiliation":32,"role":33},"Ashish Khanna, MD","Atrium Health Wake Forest Baptist","PRINCIPAL_INVESTIGATOR",[35,39],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","513-658-5866","ashish.khanna@wfusm.edu",{"name":40,"role":36,"phone":41,"phoneExt":25,"email":42},"Lynnette Harris, RN","336-716-8791","lynnette.harris@advocatehealth.org",[44,71],{"facility":45,"status":25,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Massachusetts General Hospital-Harvard","Boston","Massachusetts","02114","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-71.05977,42.35843,{"lat":55,"lon":54},[58,61,64,65,66,69],{"name":59,"role":36,"phone":25,"phoneExt":25,"email":60},"Michael R Filbin, MD, MS","mfilbin@mgh.harvard.edu",{"name":62,"role":36,"phone":25,"phoneExt":25,"email":63},"Daniel E Leisman, MD","dleisman@mgh.harvard.edu",{"name":59,"role":33,"phone":25,"phoneExt":25,"email":25},{"name":62,"role":33,"phone":25,"phoneExt":25,"email":25},{"name":67,"role":68,"phone":25,"phoneExt":25,"email":25},"Marcia Goldberg, MD","SUB_INVESTIGATOR",{"name":70,"role":68,"phone":25,"phoneExt":25,"email":25},"Kathryn Hibbert, MD",{"facility":32,"status":25,"city":72,"state":73,"zip":74,"country":49,"countryCode":50,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Winston-Salem","North Carolina","27157",{"type":52,"coordinates":76},[77,78],-80.24422,36.09986,{"lat":78,"lon":77},[81,83,86,87,89,91],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":82},"akhanna@wakehealth.edu",{"name":84,"role":36,"phone":41,"phoneExt":25,"email":85},"Lynnette C Harris, BSN","lcharris@wakehealth.edu",{"name":31,"role":33,"phone":25,"phoneExt":25,"email":25},{"name":88,"role":68,"phone":25,"phoneExt":25,"email":25},"Christopher Schaich, PhD",{"name":90,"role":68,"phone":25,"phoneExt":25,"email":25},"Daniel C Files, MD",{"name":92,"role":33,"phone":25,"phoneExt":25,"email":25},"Mark Chappell, PhD",{"type":94,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[96],{"name":97,"class":98},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100573474","phase-4-mechanistic-assessment-of-norepinephrine-therapy-vs-angiotensin-ii-in-septic-shock-100573474",false,"NCT06746753","Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock","Mechanistic Assessment of Norepinephrine TheRapy vs. Angiotensin-II in Septic Shock (MANTRA) Grant Submission- Dysfunctional Renin-Angiotensin System in Septic Shock","MANTRA","Inclusion Criteria:\n\n\\- The presence of septic shock, defined by sepsis-3 criteria: 1-adult patients (18 years or older) with septic shock, defined by SEPSIS-3 criteria: a) suspected or known infection, b) hypotension requiring vasopressors, and c) lactate \\>2mmol\u002FL 2-receiving either norepinephrine or phenylephrine with or without additional vasopressor support 3- total norepinephrine equivalent dose (NED) ≥0.1 mcg\u002Fkg\u002Fmin and ≤0.5 mcg\u002Fkg\u002Fmin, to maintain a MAP of at least 65 mmHg, is required for randomization 4-ability to consent and randomize within 24 hrs of first reaching NED threshold and within 48 hrs of hospital arrival\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Prisoners\n* Pregnant women\n* Patients for whom urgent surgery is anticipated\n* Leukocyte count \\\u003C1,000 cells\u002FμL\n* Absolute monocyte count \\\u003C200 cells\u002FμL\n* Bone marrow transplant within the past 30 days\n* Patients that will be withdrawing aggressive resuscitation, including withdraw of vasopressor support\n* transfer from outside ICU\n* history of liver cirrhosis with Child-Pugh score ≥6","ALL","18 Years",{"count":110,"type":111},78,"ESTIMATED","INTERVENTIONAL",[114],"PHASE4","Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are better predictors of septic shock severity. This approach may inform more appropriate treatment regimens and improve outcomes for these patients.",[117],"Septic Shock",[119,120,121],"sepsis","kidney disease","intensive care","NOT_YET_RECRUITING","2026-06-02",{"date":125,"type":126},"2026-06-04","ACTUAL",{"date":128,"type":111},"2026-07",{"date":130,"type":111},"2028-10-07",{"name":5,"class":6},2]